Abstract:
Availability of onsite CyP evaluation during EUS FNA of SPL can increase diagnostic yield of malignancy with a significantly lower number of EUS-FNA passes. However, studies on clinical impact of onsite CyP have reported conflicting results and considerable additional resources are required to have onsite CyP available at a facility.
Citation:
Wani, S., Rastogi, A., Early, D. S., Mullady, D., Collins, B. T., Wang, J. F., ... & Brauer, B. C. (2013). Cost minimization analysis of onsite cytopathologist (CyP) evaluation during EUS FNA of solid pancreatic lesions (SPL). Gastrointestinal Endoscopy, 77(5), AB243-AB244.